While no one wants to go to the doctor, we realize that it is something that has to be done every now and then in order to stay healthy. If you don’t have a doctor, it is recommended that you find one and become a patient with them. Should you just settle for the first doctor you find? While all doctors will be medically certified, some will be better for you than others. Here are some qualities to look for in a general practitioner.

A Warm Personality

One of the most important things to look for in a GP is how comfortable you are around them. Why does this matter? Doctors will be performing physicals on you and will, at times, be dealing with intimate areas of your body. If you are uncomfortable with them, this will be a challenging thing to do. The experts at https://www.broadgategp.co.uk/ recommended going around to several doctors and setting up a meeting with them. This will give you an idea about their personality and how they will act.

If you are uncomfortable around one of them, then it is recommended that you do not choose them as your GP. You will know you have found the right GP when you are able to feel comfortable around them even when you are put in awkward situations. Always look for a GP with a warm personality that you feel comfortable around.

Looking Out for Patient Wellbeing

While it might sound strange, you want to find a GP that is genuinely looking out for you and your well-being. Some GPs will just prescribe drugs whenever there is an issue and send you right out of the office. However, the problem with the medication is that it can have plenty of side effects, and it might not even be the right drug for what you are dealing with.

A good GP is one that takes time to diagnose the patient and waits to see what is happening before prescribing anything. While you want to make sure your GP is not afraid to give you medication, you don’t want someone who will give things out on a whim. A GP who takes the time to get a full diagnosis before coming up with a treatment plan and prescribing medication is a GP that you will want.

Medical Specialties

While all GPs are equipped to handle standard medical procedures, you might have a health condition that requires further insight. Generally, a GP will specialize in several areas and will be able to assist you in those far better than a standard GP. It is important to look for something like this, as you will most likely be seeing them often to deal with these kinds of issues. Find a doctor that can look out for your needs and can do it better than others in the area.

Understanding

You want to find a doctor who will understand the situations you are going through and the problems you are having. We don’t mean to use your doctor as a therapist, but someone who can connect and understand the medical issues you are having on a more personal level. Look for a GP who understands what you are saying about your body and your health and then acts upon it. No one knows your body better than yourself, and a good GP will understand that if you are offering any advice, it is something that should be considered.

Honesty

Honesty within the medical field is a double-edged sword. While GPs have to be honest with their patients, being too honest can bring grief and strife. At the end of the day, wouldn’t you want to know everything that is going on, though? A good GP is someone who is able to have a difficult conversation with you regarding health and will then work on follow up steps to prevent things from getting worse. Studies have shown that 1 in 10 GPs has admitted to lying to their patients to avoid causing any problems. Find someone who is not afraid to do the right thing, even if it is extremely difficult.

These are all qualities that you should look for in a GP. It can be tough to find someone you are comfortable with, but you will eventually find one if you keep looking. While we do want to avoid the doctor’s office, we must understand that there will be a time when we have to go there to get treatment. Ensure that you are with the right GP so that visits will be as painless as possible.

Magnolia Medical Technologies, Inc. – the trusted solution for reducing blood culture contamination announced the launch of its new Steripath® Micro Initial Specimen Diversion Device®. Micro is the first FDA 510(k)-cleared device indicated to reduce blood culture contamination,1 designed to be used with the most vulnerable patient populations.

Working closely with leading hospitals throughout the country, Magnolia developed the new lightweight, lower diversion volume, easy-to-use Steripath Micro with syringe-driven diversion and collection. The new device leverages the trusted ISDD®technology while diverting less than 1.0 mL of blood, engineered for patients with low-blood volume and difficult venous access.

“We are pleased to introduce the Steripath Micro platform as an integral part of our expanding ISDD portfolio designed for use with our most precious patient populations,” said Greg Bullington, CEO of Magnolia Medical. “This new product introduction has broadened the Steripath portfolio, enabling us to address the wide variety of use cases associated with blood culture collection. We are committed to establishing the new standard of care for sepsis testing accuracy for all patient populations with a focus on preventing patient harm by reducing false-positive diagnostic test results.”

Specifically, the Steripath Micro architecture uses syringe-driven negative pressure to divert and sequester the initial 0.6 to 0.9 mL of blood. Once diversion is complete the user simply presses a button to isolate the diverted blood and automatically a second independent blood flow pathway opens to collect the blood specimen for culture into the syringe.

The patented Steripath® ISDD® product portfolio, including the Steripath Gen2 direct-to-media and syringe configurations in addition to Steripath Micro, are the only FDA 510(k)-cleared devices indicated to reduce blood culture contamination.1

Steripath is a clinically proven solution to address a significant hidden problem in healthcare: the misdiagnosis of sepsis.2,3Improving the accuracy of diagnostic test results for sepsis can reduce unnecessary antibiotic treatment. This helps to address the growing threat of antibiotic-resistance, decreases hospital length of stay and associated healthcare-acquired infections while significantly reducing avoidable hospital costs.5,6

Magnolia Medical Technologies develops, manufactures and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency and predictability of critical laboratory tests. Magnolia Medical invented and patented the initial specimen diversion technique (ISDT™) and device (ISDD®) for blood culture collection and contamination prevention. The company has amassed an intellectual property portfolio including more than 70 issued method, apparatus and design patents with more than 50 additional patent applications pending.

Helix Technologies, Inc. and Medical Outcomes Research Analytics, LLC announced they have entered into an agreement to combine, creating an innovative healthcare information, analytics and technology organization. The combination will be accomplished by both companies becoming wholly owned subsidiaries of a newly formed company, Forian Inc. Upon completion of the all-stock transaction, MOR Analytics members will own approximately 72 percent and Helix shareholders will own approximately 28 percent of the combined company on a fully diluted basis. Helix shareholders will receive .027 shares of Forian common stock for each share of Helix common stock. The Forian shares received by the Helix shareholders and MOR Analytics members in the merger are expected to be treated as a tax-free exchange for federal income tax purposes. Additionally, at the time of the combination, it is expected that Forian will have in excess of $10 million in cash available. Forian will not incur any new debt to affect the combination.

“We are thrilled to add Helix’s unique technology and information assets to our innovative de-identified patient health data and analytics platform. We have created the nation’s only HIPAA compliant, Real World Evidence platform integrating cannabis and de-identified healthcare data designed to support SaaS based business performance analytics, product safety and efficacy surveillance solutions, and evidence-based health outcomes research. Our U.S.-based healthcare and cannabis clients can leverage data-driven insights to achieve improved patient health outcomes and business performance. We are excited to welcome the Helix platform and recognize the top-tier results produced by Zachary and his team over the last several years,” said MOR Analytics Chief Executive Officer, Dan Barton.

“As Helix has grown into one of the leading global providers of software used in the cannabis industry, we have prioritized value-added solutions, innovation and outstanding execution at every opportunity. With today’s important announcement, this commitment is being taken to the next level. Joining with MOR adds a completely new and critical dimension to Helix’s capabilities that will further advance the commercial success of customers using our BioTrack and Cannalytics technology suites,” said Helix’s CEO Zachary Venegas.

MOR Analytics was founded by WebMD alumni Adam Dublin and Max Wygod, and its early financings were led by visionary healthcare entrepreneur Marty Wygod. Over the last four decades, Marty Wygod has delivered some of the most innovative and successful publicly-traded healthcare companies (Medco, Emdeon, and WebMD, among others) addressing the needs of patients, physicians, and life science companies while utilizing technology and data to reduce the cost of healthcare for millions across the globe.

About Helix Technologies, Inc.

Helix’s industry-leading compliance and point of sale technologies are tailored to the unique needs of the quickly evolving cannabis industry, offering customers seamless compliance management solutions and earning government contracts in this rapidly growing market. The BioTrack cutting-edge platform is designed to scale alongside the cannabis industry. The Helix’s leadership team has deep experience in entrepreneurship, mergers and acquisitions, technology and security. With headquarters in Denver, Colorado and teams based in Florida, Washington, Hawaii, Nevada, and Argentina, Helix is committed to providing highly sophisticated and secure operating environments.

Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). This next-generation infusion system model will replace the company’s current infusion system.

Vittorio Puppo, President and CEO of Bracco Diagnostics Inc. said, “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and isthe culmination of thoughtful design and feedback from healthcare providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”

Designed for efficiency, flexibility, and ease of use

Developed with clinicians and nuclear medicine technologists in mind, the new infusion system is elegantly designed with intuitive and ergonomic details that provide easy access to all system components while minimizing radiation exposure for staff and patients.

Other smart features enable work flow efficiencies that can save nearly an hour at the beginning of each day of patient imaging and eliminate manual record keeping. A choice of dosing options and other protocol parameters make changes in scheduling and patient needs easy to accommodate.

Bracco’s commitment to excellence in cardiac PET imaging
“Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989,” said Kim McDaniel, Senior Director, Nuclear Medicine Sales and Market Support. “Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease,and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”

About Bracco Imaging S.p.A.Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider, headquartered in Milan, Italy.Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. Bracco Imaging has a strong presence in key geographies: North America, China, Europe, Japan, Brazil, Mexico and South Korea.